Clinical trials are an important way to improve treatment for people with cancer. While most are continuing during the COVID-19 pandemic, the period of time that clinical trials are available and recruiting may change quickly. If you would like to get involved in a clinical trial, speak to your treatment team or the health service where the clinical trial is being undertaken, to confirm it is open and appropriate for you. For cancer information and support, call Cancer Council's experienced cancer nurses on 13 11 20 Monday to Friday from 9am-5pm.

AALL1731 : A Phase 3 Trial Investigating Blinatumomab (NSC# 765986) in Combination With Chemotherapy in Patients With Newly Diagnosed Standard Risk or Down Syndrome B-Lymphoblastic Leukemia (B-ALL) and the Treatment of Patients With Localized B-Lymphoblastic Lymphoma (B-LLy)

Male or<br/>FemaleGender Male or
Female

RecruitingStatus Recruiting

Systemic<br/>Therapy TrialTypeSystemic
Therapy Trial

ThreePhase Three

1-31Age 1-31

Blood<br/>CancersCancer LocationBlood
Cancers

Systemic therapy | Blood / Myeloma / LymphomaAcute Lymphoblastic Leukaemia,Acute Lymphoblastic Lymphoma,Leukaemia,Lymphoma

Trial Overview Read MoreRead more

This Phase III trial is evaluating how well targeted therapy (blinatumomab) works in combination with chemotherapy in treating people with newly diagnosed, standard risk B-lymphoblastic leukaemia or B-lymphoblastic lymphoma..
 

This trial is treating patients with B Acute Lymphoblastic Leukaemia B Lymphoblastic Lymphoma.

This is a systemic therapy trial.

You may be able to join this trial if:

  • You have been diagnosed with cancer, but have not received any treatment.

You may be excluded from this trial if:

  • You have a certain disease or psychological condition.
  • You have been diagnosed with a prior or secondary type of cancer.
  • You have had certain treatments, surgical procedures or drugs.

Clinical trials have complex eligibility criteria - talk to your doctor about your interest in this trial.

Clinical Summary Read MoreRead more

Trial Identifiers

Use the hyperlinks, where available to access additional clinical trial information.

Scientific Title

A Phase 3 Trial Investigating Blinatumomab (NSC# 765986) in Combination With Chemotherapy in Patients With Newly Diagnosed Standard Risk or Down Syndrome B-Lymphoblastic Leukemia (B-ALL) and the Treatment of Patients With Localized B-Lymphoblastic Lymphoma (B-LLy)

Other Non-Commercial Sponsor

National Cancer Institute (NCI)

Summary

This is a randomised, open-label trial with multiple active comparator and experimental arms investigating Blinatumomab in combination with chemotherapy in patients with newly diagnosed standard risk or Down Syndrome B-Lymphoblastic Leukaemia (B-ALL) and the treatment of patients with localised B-Lymphoblastic Lymphoma (B-LLy). The trial is seeking to determine whether the addition of 2 cycles of blinatumomab to standard therapy improves disease-free survival.

Recruiting Hospitals Read MoreRead more

Monash Children's Cancer Centre
Clayton
Ms Irina Arzhintar
Irina.Arzhintar@monashhealth.org
(03) 8572 3490

Trial Overview: General information about a clinical trial. This section provides an overview of who might be able to join this trial and what type of treatment is involved.

Next